1. Home
  2. SGRP vs BLRX Comparison

SGRP vs BLRX Comparison

Compare SGRP & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SPAR Group Inc.

SGRP

SPAR Group Inc.

N/A

Current Price

$0.73

Market Cap

15.5M

ML Signal

N/A

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$3.66

Market Cap

12.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGRP
BLRX
Founded
1967
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.5M
12.6M
IPO Year
1996
2010

Fundamental Metrics

Financial Performance
Metric
SGRP
BLRX
Price
$0.73
$3.66
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$19.00
AVG Volume (30 Days)
54.9K
44.6K
Earning Date
03-31-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$136,104,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$2.15
52 Week High
$1.41
$6.59

Technical Indicators

Market Signals
Indicator
SGRP
BLRX
Relative Strength Index (RSI) 63.76 67.08
Support Level $0.74 $3.48
Resistance Level $0.80 $3.93
Average True Range (ATR) 0.04 0.26
MACD 0.01 0.05
Stochastic Oscillator 99.82 75.18

Price Performance

Historical Comparison
SGRP
BLRX

About SGRP SPAR Group Inc.

SPAR Group Inc is a merchandising and brand marketing services company, providing a broad range of sales-enhancing services to retailers across classes of trade and consumer goods manufacturers and distributors. The company provides five principal types of services: Merchandising, Marketing and Category Management, Remodel and Retail Transformation, Assembly and Installation, Fulfilment and Distribution, and Business Analytics and Insights. It operates in two segments, namely the U.S. and Canada, with the majority of the revenues deriving from the U.S. segment.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: